Extraintestinal Pathogenic Escherichia coli

Vaccines for Biodefense and Emerging and Neglected Diseases

Volumn , Issue , 2009, Pages 939-961

  Russo, Thomas A ^a,b   Johnson, James R ^c  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884438736     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-369408-9.00048-2     Document Type: Chapter

References (242)

1. Aguero M.E., De La Fuente G., Vivaldi E., Cabello F. ColV increases the virulence of Escherichia coli K1 strains in animal models of neonatal meningitis and urinary infection. Med. Microbiol. Immunol. 1989, 178:211-216.
2. Ahmed R., Lanier J., Pamer E. Immunological memory and infection. Immunology of Infectious Diseases 2002, ASM Press, Washington DC. S. Kaufmann, A. Sher, R. Ahmed (Eds.).
3. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 1992, 20:864-875. American College of Chest Physicians-Society of Critical Care Medicine Consensus Conference.
4. Angus D., Linde-Zwirble W., Lidlicker J., Clermont G., Carcillo J., Pinsky M. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29:1303-1310.
5. Arthur M., Johnson C.E., Rubin R.H., Arbeit R.D., Campanelli C., Kim C., Steinbach S., Agarwal M., Wilkinson R., Goldstein R. Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli. Infect. Immun. 1989, 57:303-313.
6. Bauer H.W., Alloussi S., Egger G., Blumlein H.M., Cozma G., Schulman C.C. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur. Urol. 2005, 47:542-548. discussion 548. Epub Jan. 21, 2005.
7. Bauer H.W., Rahlfs V.W., Lauener P.A., Blessmann G.S. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int. J. Antimicrob. Agents 2002, 19:451-456.
8. Bauer R., Zhang L., Foxman B., Siitonen A., Jantunen M., Saxen H., Marrs C. Molecular epidemiology of 3 putative virulence genes for Escherichia coli urinary tract infection- usp, iha, and iroN ( E. coli). J. Infect. Dis. 2002, 185:1521-1524.
9. Bernard G., Vincent J., Laterre P., Larosa S., Dhainaut J., Lopez-Rodriguez A., Steingrub J., Garber G., Helterbrand J., Ely E., Fisher C.J. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 2001, 344:699-709. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.
10. Bertin Y., Girardeau J.-P., Darfeuille-Michaud A., Contrepois M. Characterization of 20K fimbria, a new adhesin of septicemic and diarrhea-associated Escherichia coli strains, that belongs to a family of adhesins with N-acetyl-D-glucosamine recognition. Infect. Immun. 1996, 64:332-342.
11. Bhakdi S., Grimminger F., Suttorp N., Walmrath D., Seeger W. Proteinaceous bacterial toxins and pathogenesis of sepsis syndrome and septic shock: the unknown connection. Med. Microbiol. Immunol. 1994, 183:119-144.
12. Bian Z., Brauner A., Li Y., Normark S. Expression of and cytokine activation by Escherichia coli curli fibers in human sepsis. J. Infect. Dis. 2000, 181:602-612.
13. Bian Z., Yan Z.-Q., Hansson G.K., Thoren P., Normark S. Activation of inducible nitric oxide synthast/nitric oxide by curli fibers leads to a fall in blood pressure during systemic Escherichia coli infection in mice. J. Infect. Dis. 2001, 183:612-619.
14. Bingen E., Bonacorsi S., Brahimi N., Denamur E., Elion J. Virulence patterns of Escherichia coli K1 strains associated with neonatal meningitis. J. Clin. Microbiol. 1997, 35:2981-2982.
15. Binns M.M., Davies D.L., Hardy K.G. Cloned fragments of the plasmid ColV, I-K94 specifying virulence and serum resistance. Nature 1979, 279:778-781.
16. Bogaerts P., Galimand M., Bauraing C., Deplano A., Vanhoof R., De Mendonca R., Rodriguez-Villalobos H., Struelens M., Glupczynski Y. Emergence of ArmA and RmtB aminoglycoside resistance 16S rRNA methylases in Belgium. J. Antimicrob. Chemother. 2007, 59:459-464. Epub Jan. 15, 2007.
17. Bolin C., Jensen A. Passive immunization with antibodies against iron-regulated outer membrane proteins protects turkeys from Escherichia coli septicemia. Infect. Immun. 1987, 55:1239-1242.
18. Brauner A., Kaijser B., Kuhn I. Recurrent Escherichia coli bacteraemia-clinical characteristics and bacterial properties. J. Infect. 1994, 28:49-57.
19. Brooks H.J.L., O'Grady F., Mcsherry M.A., Cattell W.R. Uropathogenic properties of Escherichia coli in recurrent urinary-tract infection. J. Med. Microbiol. 1980, 13:57-68.
20. Burns S.M., Hull S.I. Loss of resistance to ingestion and phagocytic killing by O(-) and K(-) mutants of a uropathogenic Escherichia coli O75:K5 strain. Infect. Immun. 1999, 67:3757-3762.
21. Caprioli A., Falbo V., Ruggeri F.M., Baldassarri L., Bisicchia R., Ippolito G., Romol E., Donelli G. Cytotoxic necrotizing factor production by hemolytic strains of Escherichia coli causing extraintestinal infections. J. Clin. Microbiol. 1987, 25:146-149.
22. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. MMWR Morb. Mortal. Wkly Rep. 1991, 40:1-17. Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP).
23. National nosocomial infections surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. Am. J. Infect. Control 1996, 24:380-388. Center for Disease Control NNIS System.
24. Clermont O., Bonacorsi S., Bingen E. The Yersinia high-pathogenicityisland is highly predominant in virulence-associated phylogenetic groups of Escherichia coli. FEMS Microbiol. Lett. 2001, 196:153-157.
25. Connell I., Agace W., Klemm P., Schembri M., Marild S., Svanborg C. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9827-9832.
26. Cook D., Guyatt G., Marshall J., Leasa D., Fuller H., Hall R., Peters S., Rutledge F., Griffith L., Mclellan A., Wood G., Kirby A. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. New Engl. J. Med. 1998, 338:791-797.
27. Couch R. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. New Engl. J. Med. 2004, 350:860-861.
28. Craven D., Barber T., Steger K., Montecalvo M. Nosocomial pneumonia in the 1990s: update of epidemiology and risk factors. Semin. Respir. Infect. 1990, 5:157-172.
29. Cross A.S., Gemski P., Sadoff J.C., Orskov F., Orskov I. The importance of the K1 capsule in invasive infections caused by Escherichia coli. J. Infect. Dis. 1984, 149:184-193.
30. Cross A.S., Opal S.M., Palardy J.E., Drabick J.J., Warren H.S., Huber C., Cook P., Bhattacharjee A.K. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 2003, 21:4576-4587.
31. Culham D.E., Dalgado C., Gyles C.L., Mamelak D., Maclellan S., Wood J.M. Osmoregulatory transporter ProP influences colonization of the urinary tract by Escherichia coli. Microbiology 1998, 144:91-102.
32. Delicato E.R., De Brito B.G., Gaziri L.C., Vidotto M.C. Virulence-associated genes in Escherichia coli isolates from poultry with colibacillosis. Vet. Microbiol. 2003, 94:97-103.
33. De Louvois J. Acute bacterial meningitis in the newborn. J. Antimicrob. Chemother. 1994, 34(Suppl. A):61-73.
34. Dozois C., Daigle F., Curtiss R.I. Identification of pathogen-specific and conserved genes expressed in vivo by an avian pathogenic Escherichia coli strain. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:247-252.
35. Dozois C.M., Dho-Moulin M., Bree A., Fairbrother J.M., Desautels C., Curtiss 3rd.R. Relationship between the Tsh autotransporter and pathogenicity of avian Escherichia coli and localization and analysis of the Tsh genetic region. Infect. Immun. 2000, 68:4145-4154.
36. Durant L., Metais A., Soulama-Mouze C., Genevard J.M., Nassif X., Escaich S. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect. Immun. 2007, 75:1916-1925. Epub Dec. 4, 2006.
37. Elhanan G., Raz R., Pitlik S., Sharir R., Konisberger H., Samra Z., Kennes Y., Drucker M., Leibovici L. Bacteraemia in a community and a university hospital. J. Antimicrob. Chemother. 1995, 36:681-695.
38. Elliott D., Kufera J., Myers R. The microbiology of necrotizing soft tissue infections. Am. J. Surg. 2000, 179:361-366.
39. Emori T., Gaynes R. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. 1993, 6:428-442.
40. Feldmann F., Sorsa L.J., Hildinger K., Schubert S. The salmochelin siderophore receptor IroN contributes to invasion of urothelial cells by extraintestinal pathogenic Escherichia coli in vitro. Infect. Immun. 2007, 75:3183-3187. Epub Mar. 12, 2007.
41. Fernandez-Beros M.E., Kissel V., Lior H., Cabello F.C. Virulence-related genes in ColV plasmids of Escherichia coli isolated from human blood and intestines. J. Clin. Microbiol. 1990, 28:742-746.
42. Fluit A., Schmitz F., Verhoef J., Group.E.S.P. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur. J. Clin. Microbiol. Infect. Dis. 2001, 20:188-191.
43. Foxman B., Frerichs R. Epidemiology of urinary tract infection. 1. Diaphragm use and sexual intercourse. Am. J. Public Health 1985, 75:1308-1313.
44. Franco S., Cornelius V., Andrews B. Long-term outcome of neonatal meningitis. Am. J. Dis. Child 1992, 146:567-571.
45. Gautam G., Khera R. Vaginal mucosal vaccine for recurrent urinary tract infections. Indian J. Urol. 2007, 23:335-336.
46. Goldhar J., Perry R., Golecki J.R., Hoschutzky H., Jann B., Jann K. Nonfimbrial, mannose-resistant adhesins from uropathogenic Escherichia coli 083:K1:H4 and 014:K?:H11. Infect. Immun. 1987, 55:1837-1842.
47. Goluszko P., Moseley S.L., Truong S.L., Kaul A., Williford J.R., Selvarangan R., Nowicki S. Development of experimental model of chronic pyelonephritis with Escherichi coli O75:K5:H- bearing Dr fimbriae. J. Clin. Invest. 1997, 99:1661-1672.
48. Gordon D.M., Stern S.E., Collignon P.J. Influence of the age and sex of human hosts on the distribution of Escherichia coli ECOR groups and virulence traits. Microbiology 2005, 151:15-23.
49. Gosbell I., Newton P., Sullivan E. Survey of blood cultures from five community hospitals in south-western Sydney, Australia, 1993-1994. Aust. N.Z. J. Med. 2000, 30:684-692.
50. Gransden W., Eykyn S., Phillips I., Rowe B. Bacteremia due to Escherichia coli: a study of 861 episodes. Rev. Infect. Dis. 1990, 12:1008-1018.
51. Grayson M., Gibbons G., Habershaw G., Freeman D., Pomposelli F., Rosenblum B., Levin E., Karchmer A. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin. Infect. Dis. 1994, 18:683-693.
52. Greenman R.L., Schein R.M., Martin M.A., Wenzel R.P., Macintyre N.R., Emmanuel G., Chmel H., Kohler R.B., Mccarthy M., Plouffe J., et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991, 266:1097-1102.
53. Grischke E.M., Ruttgers H. Treatment of bacterial infections of the female urinary tract by immunization of the patients. Urol. Int. 1987, 42:338-341.
54. Grünberg J., Perry R., Hoschützky H., Jann B., Jann K., Goldhar J. Nonfimbrial blood group N-specific adhesin (NFA-3) from Escherichia coli O2O:KX104:H-, causing systemic infection. FEMS Microbiol. Lett. 1988, 56:241-246.
55. Guyer D.M., Henderson I.R., Nataro J.P., Mobley H.L. Identification of Sat, an autotransporter toxin produced by uropathogenic Escherichia coli. Mol. Microbiol. 2000, 38:53-66.
56. Guyer D.M., Radulovic S., Jones F.E., Mobley H.L. Sat, the secreted autotransporter toxin of uropathogenic Escherichia coli, is a vacuolating cytotoxin for bladder and kidney epithelial cells. Infect. Immun. 2002, 70:4539-4546.
57. Hagan E.C., Mobley H.L. Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection. Infect. Immun. 2007, 75:3941-3949. Epub May 21, 2007.
58. Harding G., Ronald A. The management of urinary tract infections: what we have learned in the last decade. Int. J. Antimicrob. Agents 1994, 4:83-88.
59. Heimer S.R., Rasko D.A., Lockatell C.V., Johnson D.E., Mobley H.L. Autotransporter genes pic and tsh are associated with Escherichia coli strains that cause acute pyelonephritis and are expressed during urinary tract infection. Infect. Immun. 2004, 72:593-597.
60. Hellman J., Zanzot E.M., Loiselle P.M., Amato S.F., Black K.M., Ge Y., Kurnick J.T., Warren H.S. Antiserum against Escherichia coli J5 contains antibodies reactive with outer membrane proteins of heterologous Gram-negative bacteria. J. Infect. Dis. 1997, 176:1260-1268.
61. Hooton T., Stamm W. Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. North Am. 1997, 11:551-581.
62. Hopkins W.J., Uehling D.T. Resolution time of Escherichia coli cystitis is correlated with levels of preinfection antibody to the infecting Escherichia coli strain. Urology 1995, 45:42-46.
63. Horan T., Culver D., Jarvis W. Pathogens causing nosocomial infections. Antimicrob. Newslett. 1988, 5:65-67.
64. Hoschützky H., Nimmich W., Lottspeich F., Jann K. Isolation and characterization of the non-fimbrial adhesin NFA-4 from uropathogenic Escherichia coli O7:K98:H6. Microb. Pathog. 1989, 6:351-359.
65. Huber M., Krauter K., Winkelmann G., Bauer H.W., Rahlfs V.W., Lauener P.A., Blessmann G.S., Bessler W.G. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int. J. Immuno-pharmacol. 2000, 22:1103-1111.
66. Ismail N., Lieu P., Lien C., Ling M. Bacteremia in the elderly. Ann. Acad. Med. Singapore 1997, 26:593-598.
67. Jackson L.A., Benson P., Neuzil K.M., Grandjean M., Marino J.L. Burden of community-onset Escherichia coli bacteremia in seniors. J. Infect. Dis. 2005, 191:1523-1529. Epub Mar. 22, 2005.
68. Janben T., Schwarz C., Preikschat P., Voss M., Philipp H.C., Wieler L.H. Virulence-associated genes in avian pathogenic Escherichia coli (APEC) isolated from internal organs of poultry having died from colibacillosis. Int. J. Med. Microbiol. 2001, 291:371-378.
69. Jann B., Jann K. Structure and biosynthesis of the capsular antigens of Escherichia coli. Curr. Top. Microbiol. Immunol. 1990, 150:19-42.
70. Jarvis W. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect. Control Hosp. Epidemiol. 1996, 17:552-557.
71. Jeannin P., Magistrelli G., Goetsch L., Haeuw J., Thieblemont N., Bonnefoy J., Delneste Y. Outer membrane protein A (OmpA): a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies. Vaccine 2002, 20:A23-A27.
72. Jeannin P., Magistrelli G., Herbault N., Goetsch L., Godefroy S., Charbonnier P., Gonzalez A., Delneste Y. Outer membrane protein A renders dendritic cells and macrophages responsive to CCL21 and triggers dendritic cell migration to secondary lymphoid organs. Eur. J. Immunol. 2003, 33:326-333.
73. Johanson I.M., Plos K., Marklund B.I., Svanborg C. Pap, papG and prsG DNA sequences in Escherichia coli from the fecal flora and the urinary tract. Microb. Pathog. 1993, 15:121-129.
74. Johnson J., Delavari P., Kuskowski M., Stell A. Phylogenetic distribution of extraintestinal virulence-associated traits in Escherichia coli. J. Infect. Dis. 2001, 183:78-88.
75. Johnson J., Delavari P., Stell A., Whittam T., Carlino U., Russo T. Molecular comparison of extraintestinal Escherichia coli isolates of the same electrophoretic lineages from humans and domestic animals. J. Infect. Dis. 2001, 183:154-159.
76. Johnson J., Kuskowski M., O'Bryan T., Maslow J. Epidemiological correlates of virulence genotype and phylogenetic background among Escherichia coli blood isolates from adults with diverse-source bacteremia. J. Infect. Dis. 2002, 185:1439-1447.
77. Johnson J., O'Bryan T., Delavari P., Kuskowski M., Stapleton A., Carlino U., Russo T. Clonal relationships and extended virulence genotypes among Escherichia coli isolates from women with a first or recurrent episode of cystitis. J. Infect. Dis. 2001, 183:1508-1517.
78. Johnson J., Oswald E., O'Bryan T., Kuskowski M., Spanjaard L. Phylogenetic distribution of virulence-associated genes among Escherichia coli isolates associated with neonatal bacterial meningitis in the Netherlands. J. Infect. Dis. 2002, 185:774-784.
79. Johnson J., Russo T. quot;Uropathogenic" Escherichia coli as agents of diverse non-urinary-tract extraintestinal infections. J. Infect. Dis. 2002, 186:859-864.
80. Johnson J., Russo T., Tarr P., Carlino U., Bilge S., Vary J.J., Stell A. Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN ( E. coli), among Escherichia coli isolates from patients with urosepsis. Infect. Immun. 2000, 68:3040-3047.
81. Johnson J., Stell A. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J. Infect. Dis. 2000, 181:261-272.
82. Johnson J., Stell A., Delavari P., Murray A., Kuskowski M., Gaastra W. Phylogenetic and pathotypic similarites between Escherichia coli isolates from human urinary tract infections in dogs and extraintestinal infections in humans. J. Infect. Dis. 2001, 183:897-906.
83. Johnson J.R. Microbial virulence determinants and the pathogenesis of urinary tract infection. Infect. Dis. Clin. North Am. 2003, 17(June):261-278.
84. Johnson J.R., Clabots C., Rosen H. Effect of inactivation of the global oxidative stress regulator oxyR on the colonization ability of Escherichia coli O1:K1:H7 in a mouse model of ascending urinary tract infection. Infect. Immun. 2006, 74:461-468.
85. Johnson J.R., Gajewski A., Lesse A.J., Russo T.A. Extraintestinal pathogenic Escherichia coli as a cause of invasive nonurinary infections. J. Clin. Microbiol. 2003, 41:5798-5802.
86. Johnson J.R., Jelacic S., Schoening L.M., Clabots C., Mobley H.L.T., Tarr P.I. The IrgA homologue adhesin (Iha) is an Escherichia coli virulence factor in murine urinary tract infection. Infect. Immun. 2005, 73:965-971.
87. Johnson J.R., Jelacic S., Schoening L.M., Clabots C., Shaikh N., Mobley H.L., Tarr P.I. The IrgA homologue adhesin Iha is an Escherichia coli virulence factor in murine urinary tract infection. Infect. Immun. 2005, 73:965-971.
88. Johnson J.R., Kaster N., Kuskowski M.A., Ling G.V. Identification of urovirulence traits in Escherichia coli by comparison of urinary and rectal E. coli isolates from dogs with urinary tract infection. J. Clin. Microbiol. 2003, 41:337-345.
89. Johnson J.R., Kuskowski M.A., Gajewski A., Soto S., Horcajada J.P., Jimenez de Anta M.T., Vila J. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J. Infect. Dis. 2005, 191:46-50. Epub Nov. 30, 2004.
90. Johnson J.R., Kuskowski M.A., Smith K., O'Bryan T.T., Tatini S. Antimicrobial-resistant and extraintestinal pathogenic Escherichia coli in retail foods. J. Infect. Dis. 2005, 191:1040-1049. Epub Mar. 1, 2005.
91. Johnson J.R., O'Bryan T.T., Kuskowski M., Maslow J.N. Ongoing horizontal and vertical transmission of virulence genes and papA alleles among Escherichia coli blood isolates from patients with diverse-source bacteremia. Infect. Immun. 2001, 69:5363-5374.
92. Johnson J.R., Oswald E., O'Bryan T.T., Kuskowski M.A., Spanjaard L. Phylogenetic distribution of virulence-associated genes among Escherichia coli isolates associated with neonatal bacterial meningitis in the Netherlands. J. Infect. Dis. 2002, 185:774-784. Epub Feb. 14, 2002.
93. Johnson J.R., Russo T.A. Extraintestinal pathogenic Escherichia coli: "the other bad E. coli". J. Lab. Clin. Med. 2002, 139:155-162.
94. Johnson J.R., Russo T.A. Molecular epidemiology of extraintestinal pathogenic (uropathogenic) Escherichia coli. Int. J. Med. Microbiol. 2005, 295:383-404.
95. E. coli , among Escherichia coli isolates from patients with urosepsis. Infect. Immun. 2000, 68:3040-3047.
96. Johnson T.J., Kariyawasam S., Wannemuehler Y., Mangiamele P., Johnson S.J., Doetkott C., Skyberg J.A., Lynne A.M., Johnson J.R., Nolan L.K. The genome sequence of avian pathogenic Escherichia coli strain O1:K1:H7 shares strong similarities with human extraintestinal pathogenic E. coli genomes. J. Bacteriol. 2007, 189:3228-3236. Epub Feb. 9, 2007.
97. Kaijser B., Ahlstedt S. Protective capacity of antibodies against Escherichia coli O and K antigens. Infect. Immun. 1977, 17:286-289.
98. Kaijser B., Larsson P., Nimmich W., Soderstrom T. Antibodies to Escherichia coli K and O antigens in protection against acute pyelonephritis. Prog. Allergy 1983, 33:275-288.
99. Kaijser B., Larsson P., Olling S. Protection against ascending Escherichia coli pyelonephritis in rats and significance of local immunity. Infect. Immun. 1978, 20:78-81.
100. Kanamura S., Kurazono H., Ishitoya S., Terai A., Habuchi T., Nakano M., Ogawa O., Yamamoto S. Distribution and genetic association of putative uropathogenic virulence factors iroN, iha, kpsMT, ompT and usp in Escherichia coli isolated from urinary tract infections in Japan. J. Urol. 2003, 170:2490-2493.
101. Kaper J.B., Nataro J.P., Mobley H.L. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2004, 2:123-140.
102. Kariyawasam S., Wilkie B.N., Gyles C.L. Construction, characterization, and evaluation of the vaccine potential of three genetically defined mutants of avian pathogenic Escherichia coli. Avian Dis. 2004, 48:287-299.
103. Kariyawasam S., Wilkie B.N., Gyles C.L. Resistance of broiler chickens to Escherichia coli respiratory tract infection induced by passively transferred egg-yolk antibodies. Vet. Microbiol. 2004, 98:273-284.
104. Kariyawasam S., Wilkie B.N., Hunter D.B., Gyles C.L. Systemic and mucosal antibody responses to selected cell surface antigens of avian pathogenic Escherichia coli in experimentally infected chickens. Avian Dis. 2002, 46:668-678.
105. Khan N.A., Wang Y., Kim K.J., Chung J.W., Wass C.A., Kim K.S. Cytotoxic necrotizing factor-1 contributes to Escherichia coli K1 invasion of the central nervous system. J. Bacteriol. 2002, 277:15607-15612.
106. Kim K.S. Escherichia coli translocation at the blood-brain barrier. Infect. Immun. 2001, 69:5217-5222.
107. Kim K.S., Itabashi H., Gemski P., Sadoff J., Warren R.L., Cross A.S. The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat. J. Clin. Invest. 1992, 90:897-905.
108. Kirkland K., Briggs J., Trivette S., Wilkinson W., Sexton D. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect. Control Hosp. Epidemiol. 1999, 20:725-730.
109. Korhonen T.K., Valtonen M.V., Parkkinen J., Vaisanen-Rhen V., Fine J., Orskov F., Orskov I., Svenson S.B., Makela P.H. Serotypes, hemolysin production, and receptor recognition of Escherichia coli strains associated with neonatal sepsis and meningitis. Infect. Immun. 1985, 48:486-491.
110. Koukalova D., Krocova Z., Vitek P., Macela A., Hajek V. Immunostimulatory activity of the vaccine used in the treatment of recurrent urinary infections. II. Bratisl. Lek. Listy 1999, 100:215-217.
111. Koukalova D., Reif R., Hajek V., Mucha Z., Vesely J., Viktorinova M., Lochman I. [Immunomodulation of recurrent urinary tract infections with Urvakol vaccine]. Bratisl. Lek. Listy 1999, 100:246-251.
112. Kruze D., Biro K., Holzbecher K., Andrial M., Bossart W. Protection by a polyvalent vaccine against challenge infection and pyelonephritis. Urol. Res. 1992, 20:177-181.
113. Kurazono H., Yamamoto S., Nakano M., Nair G.B., Terai A., Chaicumpa W., Hayashi H. Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein. Microb. Pathog. 2000, 28:183-189.
114. Lane M.C., Lockatell V., Monterosso G., Lamphier D., Weinert J., Hebel J.R., Johnson D.E., Mobley H.L. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Infect. Immun. 2005, 73:7644-7656.
115. Langermann S., Mollby R., Burlein J., Palaszynski S., Auguste C., De Fusco A., Al.E. Vaccination with FimH adhesin protects cynomologus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 2000, 181:774-778.
116. Langermann S., Palaszynski S., Barnhart M., Auguste G., Pinkner J., Burlein J., Al.E. Prevention of mucosal Escherichia coli infection by Fim-H-adhesin-based systemic vaccination. Science 1997, 276:607-611.
117. Lartigue M.F., Poirel L., Poyart C., Reglier-Poupet H., Nordmann P. Ertapenem resistance of Escherichia coli. Emerg. Infect. Dis. 2007, 13:315-317.
118. Le Bougenec C., Lalioui L., Du Merle L., Jouve M., Courcoux P., Bouzari S., Selvarangan R., Nowicki B.J., Y G., Andremont A., Gounon P., Garcia M.-I. Characterization of AfaE adhesins produced by extraintestinal and intestinal human Escherichia coli isolates: PCR assays for detection fo Afa adhesins that do or do not recognize Dr blood group antigens. J. Clin. Microbiol. 2001, 39:1738-1745.
119. Le Bouguenec C., Servin A.L. Diffusely adherent Escherichia coli strains expressing Afa/Dr adhesins (Afa/Dr DAEC): hitherto unrecognized pathogens. FEMS Microbiol. Lett. 2006, 256:185-194.
120. Lepow M.L., Beeler J., Randolph M., Samuelson J.S., Hankins W.A. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J. Infect. Dis. 1986, 154:1033-1036.
121. Linggood M.A., Ingram P.L. The role of alpha haemolysin in the virulence of Escherichia coli for mice. J. Med. Microbiol. 1982, 15:23-30.
122. Lundrigan M.D., Webb R.M. Prevalence of ompT among Escherichia coli isolates of human origin. FEMS Microbiol. Lett. 1991, 97:51-56.
123. Marinova S., Nenkov P., Markova R., Nikolaeva S., Kostadinova R., Mitova I., Vretenarska M. Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections. Int. J. Immunopathol. Pharmacol. 2005, 18:357-473.
124. Marklund B.I., Tennent J.M., Garcia E., Hamers A., Baga M., Lindberg F., Gaastra W., Normark S. Horizontal gene transfer of the Escherichia coli pap and prs pili operons as a mechanism for the development of tissue-specific adhesive properties. Mol. Microbiol. 1992, 6:2225-2242.
125. Marre R., Hacker J. Role of S- and common-type 1-fimbriae of Escherichia coli in experimental upper and lower urinary tract infection. Microb. Pathog. 1987, 2:223-226.
126. Maslow J.N., Mulligan M.E., Adams K.S., Justis J.C., Arbeit R.D. Bacterial adhesins and host factors: role in the development and outcome of Escherichia coli bacteremia. Clin. Infect. Dis. 1993, 17:89-97.
127. Maslow J.N., Mulligan M.E., Arbeit R.D. Recurrent Escherichia coli bacteremia. J. Clin. Microbiol. 1994, 32:710-714.
128. Mcbean M., Rajamani S. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986-1997. J. Infect. Dis. 2001, 183:596-603.
129. Mccarthy, E. Inpatient utilization of short-stay hospitals, by diagnosis: United States 1980. Hyattsville, MD:National Center for Health Statisitcs, 1983. DHHS publication no. (PHS) 83-1735.
130. Mcgregor A., Colligan P. Bacteraemia and fungaemia in an Australian general hospital-associations and outcomes. Med. J. Aust. 1993, 158:671-674.
131. Minino A., Smith B. Deaths: preliminary data for 2000. Natl. Vital Stat. Rep. 2001, 49:1-40.
132. Mitsumori K., Terai A., Yamamoto S., Ishitoya S., Yoshida O. Virulence characteristics of Escherichia coli in acute bacterial prostatitis. J. Infect. Dis. 1999, 180:1378-1381.
133. Mitsumori K., Terai A., Yamamoto S., Yoshida O. Identification of S, F1C and three PapG fimbrial adhesins in uropathogenic Escherichia coli by polymerase chain reaction. FEMS Immunol. Med. Microbiol. 1998, 21:261-268.
134. Mobley H.L.T., Chippendale G.R., Tenney J.H., Hull R.A., Warren J.W. Expression of type 1 fimbriae may be required for persistence of Escherichia coli in the catheterized urinary tract. J. Clin. Microbiol. 1987, 25:2253-2257.
135. Mobley H.L.T., Jarvis K.G., Elwood J.P., Whittle D.I., Lockatell C.V., Russell R.G., Johnson D.E., Donnenberg M.S., Warren J.W. Isogenic P-fimbrial deletion mutants of pyelonephritogenic Escherichia coli: the role of aGal(1-4)-bGal binding in virulence of a wild-type strain. Mol. Microbiol. 1993, 10:143-155.
136. Montenegro M.A., Bitter-Suermann D., Timmis J.K., Aguero M.E., Cabello F.C., Sanyal S.C., Timmis K.N. traT gene sequences, serum resistance and pathogenicity-related factors in clinical isolates of Escherichia coli and other Gram-negative bacteria. J. Gen. Microbiol. 1985, 131:1511-1521.
137. Moulin-Schouleur, M., Reperant, M., Laurent, S., Bree, A., Mignon-Grasteau, S., Germon, P., Rasschaert, D. and Schouler, C. Extra-intestinal pathogenic Escherichia coli of avian and human origin: link between phylogenetic relationships and common virulence patterns.
138. Muder R. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am. J. Med. 1998, 105:319-330.
139. Mulvey M.A., Schilling J.D., Martinez J.J., Hultgren S.J. Bad bugs and beleaguered bladders: Interplay between uropathogenic Escherichia coli and innate host defenses. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8829-8835.
140. Murphy, S. Deaths: Final Data for 1998. National Vital Statistics reports, 2000; 48.
141. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., Spyr C., Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 2004, 350:896-903.
142. Nataro J.P., Mai V., Johnson J., Blackwelder W.C., Heimer R., Tirrell S., Edberg S.C., Braden C.R., Glenn Morris J., Hirshon J.M. Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut. Clin. Infect. Dis. 2006, 43:402-407. Epub Jul. 11, 2006.
143. Negre V.L., Bonacorsi S., Schubert S., Bidet P., Nassif X., Bingen E. The siderophore receptor IroN, but not the high-pathogenicity island or the hemin receptor ChuA, contributes to the bacteremic step of Escherichia coli neonatal meningitis. Infect. Immun. 2004, 72:1216-1220.
144. Nenkov P., Mitov I., Marinova S., Markova R. Experimental investigations on the immunomodulating activity of polybacterial preparation for peroral immunotherapy and immunoprophylaxis of uroinfections. Int. J. Immunopharmacol. 1995, 17:489-496.
145. Nicolle L.E. Asymptomatic bacteriuria: review and discussion of the IDSA guidelines. Int. J. Antimicrob. Agents. 2006, 28:S42-S48. Epub Jul. 10, 2006.
146. Nowicki B., Labigne A., Moseley S., Hull R., Hull S., Moulds J. The Dr hemagglutinin, afimbrial adhesins AFA-I and AFA-III, and F1845 fimbriae of uropathogenic and diarrhea-associated Escherichia coli belong to a family of hemagglutinins with Dr receptor recognition. Infect. Immun. 1990, 58:279-281.
147. Nowicki B., Svanborg Eden C., Hull R., Hull S. Molecular analysis and epidemiology of the Dr hemagglutinin of uropathogenic Escherichia coli. Infect. Immun. 1989, 57:446-451.
148. O'Hanley P., Lalonde G., Ji G. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the Balb/c mouse model of pyelonephritis. Infect. Immun. 1991, 59:1153-1161.
149. O'Hanley P., Low D., Romero I., Lark D., Vosti K., Falkow S., Schoolnik G. Gal-Gal binding and hemolysin phenotypes and genotypes associated with uropathogenic Escherichia coli. N. Engl. J. Med. 1985, 7:414-420.
150. O'Hanley P., Marcus R., Baek K.H., Denich K., Ji G.E. Genetic conservation of hlyA determinants and serological conservation of HlyA: basis for developing a broadly cross-reactive subunit Escherichia coli alpha-hemolysin vaccine. Infect. Immun. 1993, 61:1091-1097.
151. Olesen B., Kolmos H.J., Orskov F., Orskov I. Escherichia coli bacteraemia in patients with and without haematological malignancies: a study of strain characters and recurrent episodes. J. Infect. 1998, 36:93-100.
152. Opal S.M., Cross A., Gemski P., Lyhte L.W. Survey of purported virulence factors of Escherichia coli isolated from blood, urine and stool. Eur. J. Clin. Microbiol. Infect. Dis. 1988, 7:425-427.
153. Opal S.M., Cross A.S., Gemski P., Lyhte L.W. Aerobactin and alpha-hemolysin as virulence determinants in Escherichia coli isolated from human blood, urine, and stool. J. Infect. Dis. 1990, 161:794-796.
154. Orskov F., Orskov I., Jann B., Jann K. Serology, chemistry, and genetics of O and K antigens of Escherichia coli. Bacteriol. Rev. 1977, 41:667-710.
155. Orskov I., Orskov F., Birch-Andersen A., Kanamori M., Svanborg Eden C.
156. Patton J., Nash D., Abrutyn E. Urinary tract infection: economic considerations. Med. Clin. North Am. 1991, 75:495-513.
157. Pauwels A., Pines E., Abboura M., Chiche I., Levy V.G. Bacterial meningitis in cirrhosis: review of 16 cases. J. Hepatol. 1997, 27:830-834.
158. Pecha B., Low D., O'Hanley P. Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model: single component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains. J. Clin. Invest. 1989, 83:2102-2108.
159. Pere A., Leinonen M., Vaisanen-Rhen V., Rhen M., Korhonen T.K. Occurrence of type-1C fimbriae on Escherichia coli strains isolates from human extraintestinal infections. J. Gen. Microbiol. 1985, 131:1705-1711.
160. Picard B., Sevali-Garcia J., Gouriou S., Al.E. The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect. Immun. 1999, 67:546-553.
161. Poulsen K., Wachmann C., Bremmelgaard A., Al.E. Survival of patients with surgical wound infection: a case-control study of common surgical interventions. Br. J. Surg. 1995, 82:208-209.
162. Rayner B., Willcox P. Community-acquired bacteraemia; a prospective survey of 239 cases. Q. J. Med. 1988, 69:907-919.
163. Restieri C., Garriss G., Locas M.C., Dozois C.M. Autotransporter-encoding sequences are phylogenetically distributed among Escherichia coli clinical isolates and reference strains. Appl. Environ. Microbiol. 2007, 73:1553-1562. Epub Jan. 12, 2007.
164. Revathi G., Puri J., Jain B. Bacteriology of burns. Burns 1998, 24:347-349.
165. Rippere-Lampe K.E., Lang M., Ceri H., Olson M., Lockman H.A., O'Brien A. Cytotoxic necrotizing factor type 1-positive Escherichia coli causes increased inflammation and tissue damage to the prostate in a rat prostatitis model. Infect. Immun. 2001, 69:5615-6519.
166. Rippere-Lampe K.E., O'Brien A.D., Conran R., Lockman H.A. Mutation of the gene encoding cytotoxic necrotizing factor type 1 (cnf(1)) attenuates the virulence of uropathogenic Escherichia coli. Infect. Immun. 2001, 69:3954-3964.
167. Roberts F., Geere I., Coldman A. A three-year study of positive blood cultures, with emphasis on prognosis. Rev. Infect. Dis. 1991, 13:34-46.
168. Roberts I.S. Bacterial polysaccharides in sickness and in health. The 1995 Fleming lecture. Microbiology 1995, 141:2023-2031.
169. Roberts J.A., Hardaway K., Kaack B., Fussell E.N., Baskin G. Prevention of pyelonephritis by immunization with P-fimbriae. J. Urol. 1984, 131:602-607.
170. Roberts J.A., Kaack M.B., Baskin G., Chapman M.R., Hunstad D.A., Pinkner J.S., Hultgren S.J. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J. Urol. 2004, 171:1682-1685.
171. Roberts J.A., Kaack M.B., Baskin G., Svenson S.B. Vaccination with a formalin-killed P-fimbriated E. coli whole-cell vaccine prevents renal scarring from pyelonephritis in the non-human primate. Vaccine 1995, 13:11-16.
172. Roberts J.A., Marklund B.-I., Ilver D., Haslam D., Kaack M.B., Baskin G., Louis M., Möllby R., Winberg J., Normark S. The Gal(a1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriaeis needed for pyelonephritis to occur in the normal urinary tract. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:11889-11893.
173. Russo T. Capsule and lipopolysaccharide. Escherichia coli: Virulence Mechanisms of a Versatile Pathogen 2002, Academic Press, London, UK. M. Donnenberg (Ed.).
174. Russo T., Brown J., Jodush S., Johnson J. The O4 specific antigen moiety of lipopolysaccharide but not the K54 group 2 capsule is important for urovirulence in an extraintestinal isolate of Escherichia coli. Infect. Immun. 1996, 64:2343-2348.
175. Russo T., Carlino U., Johnson J. Identification of ireA, a new iron regulated virulence gene in an extraintestinal pathogenic isolate of Escherichia coli. Infect. Immun. 2001, 69:6209-6216.
176. Russo T., Carlino U., Mong A., Jodush S. Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine. Infect. Immun. 1999, 67:5306-5314.
177. Russo T., Jodush S., Brown J., Johnson J. Identification of two previously unrecognized genes ( guaA, argC) important for uropathogenesis. Mol. Microbiol. 1996, 22:217-229.
178. Russo T., Johnson J. A proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J. Infect. Dis. 2000, 181:1753-1754.
179. Russo T., Johnson J. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect. 2003, 5:449-456.
180. Russo T., Liang Y., Cross A. The presence of K54 capsular polysaccharide increases the pathogenicity of Escherichia coli in vivo. J. Infect. Dis. 1994, 169:112-118.
181. Russo T., Mcfadden C., Carlino U., Beanan J., Barnard T., Johnson J. IroN functions as a siderophore receptor and is a urovirulence factor in an extraintestinal pathogenic isolate of Escherichia coli. Infect. Immun. 2002, 70:7156-7160.
182. Russo T., Moffitt M., Hammer C., Frank M. TnphoA mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity. Infect. Immun. 1993, 61:3578-3582.
183. Russo T., Stapleton A., Wenderoth S., Hooton T., Stamm W. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infection. J. Infect. Dis. 1995, 172:440-445.
184. Russo T.A., Beanan J.M., Olson R., Genagon S.A., Macdonald U., Cope J.J., Davidson B.A., Johnston B., Johnson J.R. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine 2007, 25:3859-3870. Epub Feb. 5, 2007.
185. Russo T.A., Davidson B.A., Carlino-Macdonald U.B., Helinski J.D., Priore R.L., Knight 3rd.P.R. The effects of Escherichia coli capsule, O-antigen, host neutrophils, and complement in a rat model of Gram-negative pneumonia. FEMS Microbiol. Lett. 2003, 226:355-361.
186. Russo T.A., Davidson B.A., Genagon S.A., Warholic N.M., Macdonald U., Pawlicki P.D., Beanan J.M., Olson R., Holm B.A., Knight 3rd.P.R. E. coli virulence factor hemolysin induces neutrophil apoptosis and necrosis/lysis in vitro and necrosis/lysis and lung injury in a rat pneumonia model. Am. J. Physiol. Lung Cell Mol. Physiol. 2005, 289:L207-L216. Epub Apr. 1, 2005.
187. Russo T.A., Johnson J.R. Extraintestinal isolates of Escherichia coli: identification and prospects for vaccine development. Exp. Rev. Vaccines 2006, 5:45-54.
188. Russo T.A., Mcfadden C.D., Carlino-Macdonald U.B., Beanan J.M., Olson R., Wilding G.E. The siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect. Immun. 2003, 71:7164-7169.
189. Russo T.A., Wang Z., Davidson B.A., Genagon S.A., Beanan J.M., Olson R., Holm B.A., Knight 3rd.P.R., Chess P.R., Notter R.H. Surfactant dysfunction and lung injury due to the E. coli virulence factor hemolysin in a rat pneumonia model. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 292:L632-L643.
190. Saccente M. Periprosthetic joint infections: a review for clinicians. Infect. Dis. Clin. Pract. 1998, 7:431-441.
191. Sader H., Jones R., Andrade-Baiocchi S., Biedenbach D. Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn. Microbiol. Infect. Dis. 2002, 44:273-280.
192. Saint S. Clinical and economic consequences of nosocomial catheter-related bacteriuria. Am. J. Infect. Control 2000, 28:68-75.
193. Salles M., Mandine E., Zalisz R., Guenounou M., Smets P. Protective effects of murine monoclonal antibodies in experimental septicemia: E. coli antibodies protect against different serotypes of E. coli. J. Infect. Dis. 1989, 159:641-647.
194. Sannes M.R., Kuskowski M.A., Owens K., Gajewski A., Johnson J.R. Virulence factor profiles and phylogenetic background of Escherichia coli isolates from veterans with bacteremia and uninfected control subjects. J. Infect. Dis. 2004, 190:2121-2128. Epub Nov. 15, 2004.
195. Sapico F. Pyogenic hematogenous spinal infections. Infect. Dis. Clin. Pract. 1999, 8:267-269.
196. Savarino S.J., Fasano A., Watson J., Martin B.M., Levine M.M., Guandalini S., Guerry P. Enteroaggregative Escherichia coli heat-stable enterotoxin 1 represents another subfamily of E. coli heat-stable toxin. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:3093-3097.
197. Schappert, S. National ambulatory medical care survey: 1992 survey. Hyattsville, MD. DHHS publication no. (PHS) 94-1250 (Advanced data for vital and health statistics no. 253), 1994.
198. Schmidt M.A., O'Hanley P., Lark D., Schoolnik G.K. Synthetic peptides corresponding to protective epitopes of Escherichia coli digalactoside-binding pilin prevent infection in a murine pyelonephritis model. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:1247-1251.
199. Schönian G., Sokolowkska-Köhler W., Rollmann R., Schubert A., Gräser Y., Presber W. Determination of S fimbriae among Escherichia coli strains from extraintestinal infections by colony hybridization and dot enzyme immunoassay. Zentralbl. Bakteriol. 1992, 276:273-279.
200. Schubert S., Picard B., Gouriou S., Heesemann J., Denamur E. Yersinia high-pathogenicity isoland contributes to virulence in Escherichia coli causing extraintestinal infections. Infect. Immun. 2002, 70:5335-5337.
201. Schubert S., Rakin A., Karch H., Carniel E., Heesemann J. Prevalence of the "high-pathogenicity island" of Yersinia species among Escherichia coli strains that are pathogenic to humans. Infect. Immun. 1998, 66:480-485.
202. Scott D.A., Kaper J.B. Cloning and sequencing of the genes encoding Escherichia coli cytolethal distending toxin. Infect. Immun. 1994, 62:244-251.
203. Selvarangan R., Goluszko P., Popov V., Singhal J., Pham T., Lublin D.M., Nowicki S., Nowicki B. Role of decay-accelerating factor domains and anchorage in internalization of Dr-fimbriated Escherichia coli. Infect. Immun. 2001, 68:1391-1399.
204. Siegman-Igra Y., Fourer B., Orni-Wasserlauf R., Golan Y., Noy A., Schwartz D., Giladi M. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin. Infect. Dis. 2002, 34:1431-1439.
205. Smit P., Oberholzer D., Hayden-Smith S., Koornhof H.J., Hilleman M.R. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977, 238:2613-2616.
206. Smith J.L., Fratamico P.M., Gunther N.W. Extraintestinal pathogenic Escherichia coli. Foodborne Pathog. Dis. 2007, 4:134-163.
207. Snyder J.A., Haugen B.J., Buckles E.L., Lockatell C.V., johnson D.E., Donnenberg M.S., Welch R.A., Mobley H.L. Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect. Immun. 2004, 72:6373-6381.
208. Sokurenko E.V., Courtney H.S., Maslow J., Siitonen A., Hasty D.L. Quantitative differences in adhesiveness of type 1 fimbriated Escherichia coli due to structural differences in fimH genes. J. Bacteriol. 1995, 177:3680-3686.
209. Somerville J.J., Cassiano L., Bainbridge B., Cunningham M., Darveau R. A novel Escherichia coli lipid A mutant that produces an antiinflammaory lipopolysaccharide. J. Clin. Invest. 1996, 97:359-365.
210. Soriano G., Coll P., Guarner C., Al.E. Escherichia coli capsular polysaccharide and spontaneous bacterial peritionitis. Hepatology 1995, 21:668-673.
211. Sorsa L.J., Feldmann F., Hildinger K., Dufke S., Schubert S. Characterization of four novel genomic regions of uropathogenic Escherichia coli highly associated with the extraintestinal virulent phenotype: a jigsaw puzzle of genetic modules. Int. J. Med. Microbiol. 2007, 297:83-95. Epub Feb. 5, 2007.
212. Stamm W., Hooton T. Management of urinary tract infection in adults. N. Engl. J. Med. 1993, 329:1328-1334.
213. Stamm W., Hooton T., Johnson J., Al.E. Urinary tract infections. J. Infect. Dis. 1989, 15:400-406.
214. Stamm W., Mckevitt M., Roberts P., White N. Natural history of recurrent urinary tract infections in women. Rev. Infect. Dis. 1991, 13:77-84.
215. Stein G.E., Craig W.A. Tigecycline: a critical analysis. Clin. Infect. Dis. 2006, 43:518-524. Epub Jun. 26, 2006.
216. Stoll B., Hansen N., Fanaroff A., Al.E. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. New Engl. J. Med. 2002, 347:240-247.
217. Talan D., Stamm W., Hooton T., Moran G., Burke T., Iravani A., Reuning-Scherer J., Church D. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000, 283:1583-1590.
218. Tambyah P.A., Knasinski V., Maki D.G. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. Infect. Control Hosp. Epidemiol. 2002, 23:27-31.
219. Torres A.G., Redford P., Welch R.A., Payne S.M. TonB-dependent systems of uropathogenic Escherichia coli: aerobactin and heme transport and TonB are required for virulence in the mouse. Infect. Immun. 2001, 69:6179-6185.
220. Troeger, H., Richter, J.F., Beutin, L., Gunzel, D., Dobrindt, U., Epple, H.J., Gitter, A.H., Zeitz, M., Fromm, M. and Schulzke, J.D. Escherichia coli alpha-haemolysin induces focal leaks in colonic epithelium: a novel mechanism of bacterial translocation. Cell Microbiol. 2007; 9:2530-2540.
221. Uehling D.T., Hopkins W.J., Elkahwaji J.E., Schmidt D.M., Leverson G.E. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J. Urol. 2003, 170:867-869.
222. Uehling D.T., Hopkins W.J., James L.J., Balish E. Vaginal immunization of monkeys against urinary tract infection with a multi-strain vaccine. J. Urol. 1994, 151:214-216.
223. Uehling D.T., Hopkins W.J., Jensen J., Balish E. Vaginal immunization against induced cystitis in monkeys. J. Urol. 1987, 137:327-329.
224. Uehling D.T., James L.J., Hopkins W.J., Balish E. Immunization against urinary tract infection with a multi-valent vaginal vaccine. J. Urol. 1991, 146:223-226.
225. Ulett G.C., Valle J., Beloin C., Sherlock O., Ghigo J.M., Schembri M.A. Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract. Infect. Immun. 2007, 75:3233-3244. Epub Apr. 9, 2007.
226. Unhanand M., Mustafa M., Mccracken G., Nelson J. Gram-negative enteric bacillary meningitis: a twenty-year experience. J. Pediatr. 1993, 122:15-21.
227. Uslan D.Z., Crane S.J., Steckelberg J.M., Cockerill 3rd.F.R., St Sauver J.L., Wilson W.R., Baddour L.M. Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Arch. Intern. Med. 2007, 167:834-839.
228. Vandemaele F., Ververken C., Bleyen N., Geys J., D'Hulst C., Addwebi T., Van Empel P., Goddeeris B.M. Immunization with the binding domain of FimH, the adhesin of type 1 fimbriae, does not protect chickens against avian pathogenic Escherichia coli. Avian Pathol. 2005, 34:264-272.
229. Vastag B. New vaccine decreases rate of nosocomial infections. JAMA 2001, 285:1565.
230. Vital and Health Statistics. Ambulatory and in-patient procedures in the United States, 1995. Hyattsville, MD: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Series 13: data from the national health care survey, no. 135, DHHS publication no. (PHS) 98-1796, 1998.
231. Weissman S.J., Chattopadhyay S., Aprikian P., Obata-Yasuoka M., Yarova-Yarovaya Y., Stapleton A., Ba-Thein W., Dykhuizen D., Johnson J.R., Sokurenko E.V. Clonal analysis reveals high rate of structural mutations in fimbrial adhesins of extraintestinal pathogenic Escherichia coli. Mol. Microbiol. 2006, 59:975-988.
232. Welch R.A., Dellinger E.P., Minshew B., Falkow S. Haemolysin contributes to virulence of extra-intestinal E. coli infections. Nature 1981, 294:665-667.
233. Wenzel R. Hospital-acquired pneumonia: overview of the current state of art for prevention and control. Eur. J. Clin Microbiol. 1989, 8:56-60.
234. Weycker D., Akhras K.S., Edelsberg J., Angus D.C., Oster G. Long-term mortality and medical care charges in patients with severe sepsis. Crit. Care Med. 2003, 31:2316-2323.
235. Whitfield C., Valvano M. Biosynthesis and expression of cell-surface polysaccharides in Gram-negative bacteria. Adv. Micro. Physiol. 1993, 35:135-246.
236. World Health Organization. The World Health Report 2000-Health Systems: Improving Performance. Geneva: World Health Organization, 2000.
237. Wroblewska-Seniuk K., Selvarangan R., Hart A., Pladzyk R., Goluszko P., Jafari A., Du Merle L., Nowicki S., Yallampalli C., Le Bouguenec C., Nowicki B. Dra/AfaE adhesin of uropathogenic Dr/Afa+ Escherichia coli mediates mortality in pregnant rats. Infect. Immun. 2005, 73:7597-7601.
238. Yamamoto S., Nakano M., Terai A., Yuri K., Nakata K., Nair G.B., Kurazono H., Ogawa O. The presence of the virulence island containing the usp gene in uropathogenic Escherichia coli is associated with urinary tract infection in an experimental mouse model. J. Urol. 2001, 165:1347-1351.
239. Zhang L., Foxman B., Tallman P., Cladera E., Le Bougenec C., Marrs C.F. Distribution of drb genes coding for Dr binding adhesins among uropathogenic and fecal Escherichia coli isolates and identification of new subtypes. Infect. Immun. 1997, 65:2011-2018.
240. Ziegler E.J., Fisher C.J., Sprung C.L., Straube R.C., Sadoff J.C., Foulke G.E., Wortel C.H., Fink M.P., Dellinger R.P., Teng N.N., et al. Treatment of Gram-negative bacteremia and septic shock with HA-1 A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1 A Sepsis Study Group. N. Engl. J. Med. 1991, 324:429-436.
241. Ziegler E.J., Mccutchan J.A., Fierer J., Glauser M.P., Sadoff J.C., Douglas H., Braude A.I. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 1982, 307:1225-1230.
242. Zoutman D., Mcdonald S., Vethanayagan D. Total and attributable costs of surgical-wound infections at a Canadian tertiary-care center. Infect. Control Hosp. Epidemiol. 1998, 19:254-259.